ArticleDiscover oncology2026
CXCL8 producing macrophages shape gastric cancer outcomes.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) remains a major cause of cancer-related mortality worldwide, highlighting the need for reliable prognostic biomarkers. Although chemokines critically regulate the tumor microenvironment (TME), their integrated prognostic value and mechanistic roles in GC remain unclear. We aimed to develop a chemokine-based prognostic signature and elucidate its underlying cellular basis.
methodsTranscriptomic data from TCGA and GEO cohorts were integrated to construct and validate a prognostic model using least absolute shrinkage and selection operator (LASSO) Cox regression based on six differentially expressed chemokines. Associations between the risk score and TME characteristics, tumor mutation burden (TMB), and drug sensitivity were evaluated. Single-cell RNA sequencing (scRNA-seq) was performed to determine the cellular origin and functional role of the key chemokine CXCL8.
resultsA six-chemokine signature stratified patients into high- and low-risk groups with significantly different overall survival (OS; p = 0.003) and progression-free survival (PFS; p < 0.001). The risk score was an independent prognostic factor, and the corresponding nomogram demonstrated good predictive performance (C-index = 0.680). The high-risk group exhibited elevated TMB and reduced chemosensitivity. scRNA-seq analysis identified macrophages as the principal source of CXCL8. These CXCL8-high macrophages displayed a pro-tumorigenic phenotype and functioned as key communication hubs within the TME, particularly through SPP1 signaling.
conclusionThis chemokine-based signature provides clinically relevant prognostic stratification in GC and implicates the CXCL8-macrophage axis as a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.